Gritstone bio, Inc. (GRTS)

2.6250 -0.0350 (-1.32%) As of 11:02AM EDT. Market open.

Gritstone bio, Inc.

5959 Horton Street
Suite 300
EmeryVille, CA 94608
United States
510 871 6100
https://gritstonebio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 233

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.	Co-Founder, Pres, CEO & Director	904.66k	N/A	1967
Mr. Erin E. Jones M.S.	Exec. VP & COO	597.74k	N/A	1972
Dr. Karin Jooss Ph.D.	Exec. VP and Head of R&D	658.03k	N/A	1965
Ms. Vassiliki Economides	Exec. VP & CFO	N/A	N/A	1981
Mr. James Cho	Chief Accounting Officer	N/A	N/A	N/A
George MacDougall	Director of Investor Relations & Corp. Communications	N/A	N/A	N/A
Ms. Stacy Proctor	Exec. VP & Chief People Officer	N/A	N/A	N/A
Dr. Matthew J. Hawryluk M.B.A., Ph.D.	Exec. VP & Chief Bus. Officer	N/A	N/A	1979
Mr. Vijay Yabannavar Ph.D.	Exec. VP & Chief Technical Devel. Officer	N/A	N/A	1962

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase 2/3 clinical trials for the treatment of solid tumors, including microsatellite stable colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Corporate Governance

Gritstone bio, Inc.’s ISS Governance QualityScore as of March 1, 2023 is 7. The pillar scores are Audit: 6; Board: 4; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.